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ABSTRACT 21 
 22 
Multi- and extensively-drug resistant (MDR and XDR) Mycobacterium tuberculosis strains 23 
represent an international health issue requiring immediate solutions. Here, we studied the 24 
susceptibility of M. tuberculosis H37Rv as well as MDR and XDR strains to a combination of 25 
a glycopeptide with a plant secondary metabolite, aloe emodine (AE). This combination 26 
showed a partial synergic effect. Further analyses of the mycobacterial envelope revealed a 27 
quite selective reduction of phthiodiolone dimycocerosate by AE concordant with the 28 
observed partial synergic effect.  29 
 30 
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Mycobacterium tuberculosis is the main etiological agent of tuberculosis (TB). This disease is 41 
an international health issue, affecting one third of worldwide population and causing 1.4 42 
million deaths annually. The emergence of multi- and extensively-drug-resistant strains 43 
(MDR-TB and XDR-TB) makes current treatment less or barely not efficient on infected 44 
patients (1). This emerging issue requires new drugs focusing on new targets. Medicinal plant 45 
drug discovery has been useful strategy providing numerous new compounds against various 46 
pathologies, including cancer and malaria (2-4). Here we studied a plant secondary 47 
metabolite, the aloe emodin (AE), exhibiting among others potential anticancer activities. 48 
The aloe emodin is an anthraquinone produced by several plants, among those the well-49 
known Aloe vera. Interestingly, Aloe vera extracts have been reported for their antibacterial 50 
properties including an antimycobacterial effect (5, 6) and aloe emodin, one of its 51 
constituents, has also been shown to possess antibacterial activities (7) and antimycobacterial 52 
activities (8). In silico studies suggested that an acyl carrier protein (ACP) synthase could be 53 
an AE target (9). 54 
The potential action of AE on an ACP synthase led us to test if it could affect the 55 
mycobacterial cell wall lipid synthesis and therefore could also synergize with vancomycin to 56 
inhibit mycobacterial cell growth. We previously showed that vancomycin was efficient only 57 
on mycobacteria possessing altered envelope, especially on those lacking phthiocerol and 58 
phthiodiolone dimycocerosates, PDIM A and PDIM B, respectively (10). This envelope is 59 
composed, from the outside, of a capsule containing selective complex waxy lipids (including 60 
PDIM A and PDIM B), which may also be present in the outer leaflet of the mycomembrane, 61 
whose inner leaflet is composed of long mycolic acids. The latter long chain fatty acids 62 
esterified the heteropolysaccharide arabinogalactan, which in turn is covalently attached to 63 
peptidoglycan (11). Enzymes specifically involved in this waxy wall synthesis belong to the 64 
fatty acid synthases (FAS) I or II pathway. The FAS I system is a multi-domain protein 65 
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complex while the FAS II system is composed of multiple enzymes with separated functional 66 
domains. Both FAS enzymes possess ACP domains. Well known anti-tuberculosis drugs are 67 
targeting FAS II enzymes, such as isoniazid (INH) inhibiting InhA enoyl ACP reductase and 68 
KasA ACP synthase, both involved in mycolic acid synthesis (12). The β-ketoacyl ACP 69 
synthase docking model described by Ramesh et al. proposed a more potent effect of AE on 70 
this enzymatic domain compared to cerulenine, a strong mycobacterial lipid synthesis 71 
inhibitor (9). This potential protein interaction is interesting considering that cerulenine can 72 
synergize with vancomycin to inhibit MDR and XDR strains growth (10). Consequently, we 73 
investigated the action of the AE on the mycobacterial lipid cell wall integrity and its ability 74 
to synergize with vancomycine to inhibit the growth of mycobacteria including different M. 75 
tuberculosis strains. 76 
Preliminary tests were performed on M. bovis BCG using the BacT/ALERT MP system. The 77 
BacT/ALERT MP bottle (10 ml) completed with restoring fluid (0.5 ml) and drugs (0.1 ml) 78 
were inoculated with a 0.5 McFarland diluted  M. bovis BCG culture (0.5 ml) grown to mid-79 
log phase in a standard 7H9 medium, with 0.05% tween and 10% ADC (albumin dextrose 80 
catalase). A dedicated bottle contained a 1/100 dilution of the initial inoculum, so that when 81 
the mycobacterial growth in the other bottles (containing drugs) were flagged positive at the 82 
same time or after the 1/100 inoculum control bottle, we could consider that the minimum 83 
inhibitory concentration (MIC or 99% inhibition of the bacterial growth) was reached at the 84 
drug concentration present in the bottles (13,14).  85 
We investigated synergy with vancomycin calculating the ΔX/ΔY ratio. ΔX corresponds to 86 
the growth index (GI) of both drugs in combination and ΔY to the lowest GI of one of these 87 
drugs alone. Synergy is reached when ΔX/ΔY quotient is < 0.5 (10). Table 1A shows ΔX/ΔY 88 
quotients obtained for M. bovis BCG treated with a combination of 10 µg/ml vancomycin 89 
with 3 µg/ml AE. Quotients obtained varied from 0.3 to > 0.5. 90 
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This combination was further studied on M. tuberculosis by the CLSI approved agar 91 
proportion method (13). Synergy was investigated following the checkerboard process. 92 
Minimal inhibitory concentration (MIC) of each drug alone (MICa or MICb) or in 93 
combination (MICab or MICba) allowed us to calculate a fractional inhibitory index (FIC), 94 
FICa : MICab/ MICa and FICb: MICba/ MICb. These FIC would allow to calculate a 95 
fractional inhibitory concentration index (FICI) : FICa + FICb. A FICI ≤ 0.5 indicates synergy 96 
of drugs “a” and “b” together (15). As shown in Table 1B, we obtained a MIC for 97 
vancomycin of 50-100 µg/ml, a MIC for AE of 12.5-25 µg/ml, a MIC for vancomycin with a 98 
fixed 2.5 µg/ml AE of 12.5-25 µg/ml and a MIC for AE with a fixed 5 µg/ml vancomycin of 99 
6.25- 12.5 µg/ml. These MICs allowed us to calculate a FICI of 0.375-1. The effect of the 100 
combination of both drugs is therefore just between a synergy and an additive effect, both on 101 
M. bovis BCG and on the H37Rv M. tuberculosis strain.  102 
The lipid composition of H37Rv M. tuberculosis exposed to AE was analyzed in order to 103 
better assess the potential effect of AE on the mycobacterial cell wall lipid synthesis. Total 104 
lipid extracts were analyzed by high performance thin layer chromatography (HPTLC) 105 
following the procedure already described by Simeone et al. (16). The HPTLC plates were 106 
scanned to measure the absorption of different spots in order to compare, in percentage, AE-107 
treated lipid extracts to drug-free extracts.  108 
Interestingly we observed a decrease of the PDIM B and triacylglycerol (TAG) and a slight 109 
decrease of PDIM A in AE-treated M. tuberculosis (Fig. 1). On the opposite, no variation in 110 
mycolic acid methyl esters (MAMES) were detected in AE-treated samples compared to the 111 
control condition (data not shown). As most of the compounds able to synergize with 112 
vancomycin against mycobacterial cell growth act by both reducing PDIM A and PDIM B 113 
lipids in the mycobacterial cell wall (10, 17), it is tempting to assume that the weak synergy 114 
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observed by the combination of AE with vancomycin could result from a less pronounced 115 
effect of AE on PDIM A. 116 
Considering that vancomycin combined with cerulenin is efficient on most MDR and XDR 117 
strains (10), we tested AE (3 µg/mL) and vancomycin (10 µg/mL), both separate and 118 
combined on a set of MDR and XDR strains by using the MGIT960/TBeXIST system 119 
according to the manufacturer's instructions. Only one strain out of 6 showed a clear synergy 120 
to the combination of AE with vancomycin, giving a ΔX/ΔY ratio of 0.099 (Table 1C). These 121 
results were confirmed by agar proportion method, showing synergy for the same XDR strain 122 
(ID W_14614) termed isolate 3 in Table 1C. AE, alone, was previously shown to be inactive 123 
on MDR and XDR strains (8). Here, we showed that AE can also rarely synergize with 124 
vancomycin on such strains. 125 
In conclusion, the combination of AE and vancomycin shows an intriguing result between a 126 
synergy and an additive effect on M. bovis BCG, M. tuberculosis H37Rv and only one out of 127 
6 MDR strains was susceptible to AE in combination with vancomycin. Lipid analysis 128 
revealed a slight decrease of PDIM A compared to PDIM B that could explain this 129 
intermediate effect of AE in combination vancomycin.  130 
Although AE is not showing a strong synergy with vancomycin, this drug should not be 131 
discarded as it could still inhibit some MDR strain. Moreover, AE is a good drug candidate 132 
acting against parasites, fungi and viruses with potential action against HIV-1 (18). 133 
Considering the frequent co-infection of M. tuberculosis with HIV, the use of a drug efficient 134 
on various pathogens would be of great interest. Obviously, the action of AE on M. 135 
tuberculosis co-infected HIV patients should be further investigated.  136 
 137 
 138 
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 195 
FIG 1 Lipid profile of 25 µg/ml AE-treated M. tuberculosis, expressed in percent compared 196 
to a DMSO-treated control condition. A. Lipid quantification of triacylglycerol (TAG), 197 
phthiocerol dimycocerosates (PDIM A) and phthiodiolone dimycocerosates (PDIM B) based 198 
on fluorometric recording of primuline-treated TLC. B. Corresponding HPTLC of TAG, 199 
PDIM A and PDIM B separated with petroleum ether/diethylether (9:1, v/v) and visualized by 200 
primuline. 201 
 202 
TABLE 1 Drug susceptibility on (A) M. bovis BCG analyzed by the BaCT/ALERT system 203 
using 3 µg/ml AE and 10 µg/ml vancomycin, on (B) M. tuberculosis H37Rv by the agar 204 
proportion method and on (C) MDR- and XDR-TB strains using the MGIT method and 3 205 
µg/ml AE and 10 µg/ml vancomycin. 206 
 207 
 208 
